RecruitingPhase 2NCT06653517
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Studying Rare odontogenic tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Principal Investigator
- CAO Wei, PHD;MDShanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Intervention
- Dabrafenib(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2023 – 2029
Study locations (1)
- Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06653517 on ClinicalTrials.govOther trials for Rare odontogenic tumor
Additional recruiting or active studies for the same condition.